Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the role of hormones in human penis development and associated conditions due to hormonal imbalances, but reports no new findings, suggesting hormone replacement can manage some conditions.

New factors in female hair loss include genetics, hormones, stress, and inflammation; future treatments should also focus on these areas and consider the patient's emotional well-being.

Modern hair restoration techniques can effectively treat hair loss and provide natural-looking results.

The document concludes that treatments for female hair loss and excess body hair are available, but managing expectations is important.

Androgens like testosterone affect skin health and can lead to conditions such as acne and hair loss, with various treatments available.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

Iron supplements may reverse premature graying in iron-deficient individuals; ingrown nails are common in diabetics with certain risk factors; topical finasteride may reduce scalp DHT as effectively as oral finasteride; monilethrix treatment is challenging but some medications can help.

Two lotions used day and night may be a good alternative to minoxidil for hair loss, with better cosmetic effects and tolerance.

This review summarizes therapeutic advances reported in English-language literature from December 1987 to December 1988 and states no new clinical results.

New treatment improves male hair loss.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

This study suggests that the newly characterized sebocytic progenitor cells HSGC1 and HSGC2 from different skin sites may have proliferative and differentiating potential in response to DHT.

In this study, the researchers highlighted the availability of new topical and systemic agents with varied mechanisms for treatment, emphasizing that the choice of agent should be tailored to individual needs and the options available in different countries.

This review posits that alopecia in PCOS results from the interaction between local follicular signaling failures, insulin resistance, inflammation, and genetic predispositions, rather than solely from androgen excess, and recommends a systems-level framework for its management.

This study found that androgen inactivation pathways in scalp sebaceous glands change with age, specifically noting that AKR1C expression, including AKR1C4 previously thought liver-specific, declines with age and is sex dependent, which could impact hair follicle health during aging.

This research reported that AKR1C enzyme expression, particularly AKR1C4, in scalp sebaceous glands decreases with age, suggesting potential age-related changes in androgen metabolism affecting hair follicle health. Additionally, sulforaphane treatment increased AKR1C expression in related cell types.

In this study, researchers found that androgen receptor expression and AKR1C-mediated androgen inactivation, including AKR1C4, are prominent in scalp sebaceous glands, with AKR1C expression decreasing with age and differing by sex, suggesting these changes may impact hair follicle health as people age.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This study found that steroid sulfatase in the dermal papilla of hair follicles metabolizes dehydroepiandrosterone sulfate to support the development of androgenetic alopecia, suggesting potential for steroid sulfatase inhibitors as treatments.

This review finds preliminary evidence suggesting that topical finasteride may significantly reduce hair loss and increase hair counts in treating androgenetic alopecia, with a promising safety profile.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This article discusses the causes, diagnosis, and treatment options for female pattern hair loss, emphasizing the role of topical minoxidil as a primary treatment, but provides no new clinical results.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

In this study, radiofrequency microporation significantly improved topical minoxidil delivery and hair regrowth in a mouse model of androgenetic alopecia, with minimal systemic exposure compared to oral administration, suggesting it could be a promising needle-free option for topical therapy.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

In this preclinical study, PA-011 derived from Periplaneta americana showed significant hair regrowth effects in androgenetic alopecia mouse models by inhibiting inflammation and oxidative stress, activating hair follicle stem cell proliferation, and normalizing skin microbiota, suggesting promise as an AGA treatment.

In this review, the authors reported that exosomal miRNA-based therapies showed promising therapeutic effects on nine skin diseases in animal models, with enhanced outcomes observed when using miRNA-overexpressing exosomes compared to natural ones; however, no comparisons to standard treatments were available.

This study identified core genes and pathways involved in androgenetic alopecia, finding that genes related to hair follicle development are down-regulated, while those linked to immune responses are up-regulated, highlighting potential therapeutic targets.

This study used computer simulations to evaluate the absorption of oral and topical finasteride for treating androgenetic alopecia, finding that topical applications resulted in lower plasma concentrations, suggesting potential viability as a treatment option.

This study observed that using only a 5 alpha-reductase inhibitor was ineffective for treating androgen-dependent hair loss in women, possibly due to differing copper levels influencing enzyme activity.